Portal hemodynamic effects of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma: a prospective cohort study
Not Applicable
Recruiting
- Conditions
- patients with advanced hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000043366
- Lead Sponsor
- Kitasato University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)Tumor invasion in intrahepatic large vessels (Vp4) 2)hepatic encephalopathy, refractory ascites 3)hypertension (160/100 or higher.) 4)Severe renal function(eGFR<50ml/min)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does the PD-L1/VEGF dual inhibition by atezolizumab and bevacizumab affect portal venous pressure in advanced HCC patients?
What are the comparative portal hemodynamic outcomes of atezolizumab/bevacizumab versus sorafenib in advanced hepatocellular carcinoma?
Which biomarkers (e.g., PD-L1 expression, VEGF levels, liver fibrosis markers) correlate with portal flow improvement in HCC patients treated with atezolizumab and bevacizumab?
What adverse event profiles and management strategies are reported for atezolizumab/bevacizumab in Kitasato University's HCC cohort study?
How do anti-angiogenic and immune checkpoint inhibitor combinations like atezolizumab/bevacizumab influence hepatic sinusoidal resistance in HCC compared to lenvatinib?